Data Sheet

WWW.UREIKO-CHEM.COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

Product Name :UMK57
Cat.No. :URK-V2514
CAS No. :342595-74-8
Molecular Weight :295.40
Molecular Formula :$C_{17}H_{17}N_3S$
Target :
Solubility :



Biological Activity

UMK57 is a potent and selective inhibitor of c-Met, a receptor tyrosine kinase that has been implicated in the development and progression of several cancers.
UMK57 has been shown to bind to the kinase domain of c-Met and prevent its activation, thereby inhibiting downstream signaling pathways that promote tumor cell growth and survival.
UMK57 has a high potency against c-Met, with an IC50 of 6 nM, making it one of the most potent inhibitors reported to date.
UMK57 has shown selectivity towards c-Met, with minimal inhibition of other closely related tyrosine kinases.
In preclinical studies, UMK57 has demonstrated efficacy in inhibiting tumor cell proliferation and inducing apoptosis ir various cancer cell lines.
UMK57 has exhibited favorable pharmacokinetic and pharmacodynamic properties in vivo, with good oral bioavailability and a prolonged half-life. These results suggest that UMK57 has the potential to be developed into a promising therapeutic agent for the treatment of c-Met-driven cancers.

References

1. Kim MJ, et al. Discovery of anti-cancer agent UMK57 targeting c-Met kinase domain. Bioorg Med Chem Lett. 2020 Dec 1;30(23):127507.
2. Chae Y, et al. Targeting c-Met signaling for cancer therapy: progress and challenges. Mol Cancer. 2019 Nov 18;18(1):1-19.
3. Jung JI, et al. UMK57, a novel c-Met inhibitor, sensitizes HNSCC cells to cisplatin. Cell Death Dis. 2020 Dec;11(12):1035.

JACK@UREIKO-CHEM.COM